Symbiotec Pharmalab IPO Listing Today: Shares Rise 11% After Flat NSE Debut; Check Price, Intraday High, Subscription and More

1 Sep 2026 , 11:49 AM

Shares of Symbiotec Pharmalab Ltd made a muted debut on the stock exchanges on Tuesday, September 1, 2026, listing at ₹988 per share on the NSE, exactly in line with the IPO issue price. However, the stock attracted strong buying interest after listing and climbed nearly 11% from its issue price during the morning session.

At 11:30 AM, Symbiotec Pharmalab shares were trading at ₹1,092.40 on the NSE, compared with the issue price of ₹988. The stock touched an intraday high of ₹1,098 and a low of ₹934.20 during the trading session.

Symbiotec Pharmalab IPO Listing: Key Details

Particulars	Details
IPO Issue Price	₹988
NSE Listing Price	₹988
Listing Gain	Nil
Current Price (11:30 AM)	₹1,092.40
Gain vs Issue Price	~10.6%
Intraday High	₹1,098
Intraday Low	₹934.20
Lot Size	15 shares
Minimum Investment	₹14,820
IPO Subscription	71.26 times

Symbiotec Pharmalab Shares List Flat on NSE

Symbiotec Pharmalab shares listed at ₹988 on the NSE, as same as the IPO issue price.  The flat debut came despite the IPO receiving exceptionally strong demand during the subscription period. The IPO issue was subscribed 71.26 times, highlighting the high level of investor interest in the pharmaceutical company.

However, the stock’s performance changed considerably after the listing. Following an initial decline to ₹934.20, shares recovered sharply and moved towards the ₹1,100 mark.

By 11:30 AM, the stock was trading at ₹1,092.40, representing a gain of around 10.6% over the IPO issue price.

Stock Touches ₹1,098 Intraday High

Significant volatility was noticed in the shares of Symbiotec Pharmalab  where the stock opened at ₹988 and then slipped to an intraday low of ₹934.20. From that level, buying interest emerged, pushing the stock higher. The shares later in the day touched an intraday high of ₹1,098, before trading at ₹1,092.40 around 11:30 AM.

This means the stock moved through a range of more than ₹160 during the early trading session, reflecting considerable volatility following its market debut.

Symbiotec Pharmalab IPO Subscription Reaches 71.26 Times

The strong post-listing move comes after the Symbiotec Pharmalab IPO received an overwhelming response from investors.

The public issue was subscribed 71.26 times, with investors placing bids for 93,52,49,700 shares against 1,31,24,929 shares available for subscription.

The category-wise subscription details were:

Investor Category	Shares Reserved	Shares Bid For	Subscription
QIBs	37,39,872	64,33,59,195	172.03x
NIIs	28,04,904	20,65,35,120	73.63x
Retail Investors	65,44,776	8,48,10,330	12.96x
Total	1,31,24,929	93,52,49,700	71.26x

What Was the Minimum Investment in Symbiotec Pharmalab IPO?

The Symbiotec Pharmalab IPO had a lot size of 15 shares.

At the issue price of ₹988 per share, investors applying for one lot had to invest:

15 × ₹988 = ₹14,820

Therefore, the minimum investment required for a retail investor was ₹14,820, excluding applicable charges.

Investors who received one lot and held their shares at ₹1,092.40 would see the value of their 15 shares rise to approximately ₹16,386, translating into an unrealised gain of around ₹1,566 compared with the IPO issue price.

Flat Listing Despite Strong IPO Demand

The flat listing of Symbiotec Pharmalab shares is notable because the IPO had attracted exceptionally high subscription levels.

Typically, heavy oversubscription can increase expectations of a strong listing, particularly when institutional participation is high. However, listing prices are influenced by market conditions, investor expectations, valuations, demand and supply dynamics, and the premium or discount investors are willing to pay once trading begins.

In Symbiotec Pharmalab’s case, the stock did not deliver a listing gain. Instead, the buying interest emerged after the shares started trading.

Symbiotec Pharmalab IPO: What Investors Should Watch

Following the initial post-listing rally, investors are likely to focus on whether the stock can sustain its gains beyond the first trading session.

Some of the key factors to watch include:

• Post-listing price performance
• Quarterly financial results
• Revenue and profit growth
• Pharmaceutical industry outlook
• Institutional investor interest
• Valuation after the listing
• Trading volumes and price volatility
• Future business growth and expansion plans

A strong listing-day move does not necessarily indicate long-term performance. Investors should therefore evaluate the company’s fundamentals and valuation alongside its market price.

Symbiotec Pharmalab IPO Listing Today: Key Takeaway

The Symbiotec Pharmalab IPO listing turned out to be a two-part story. The shares made a flat debut at ₹988 on the NSE, giving IPO allottees no listing gain. However, the stock subsequently attracted buying interest and climbed to an intraday high of ₹1,098.

At 11:30 AM, Symbiotec Pharmalab shares were trading at ₹1,092.40, up around 10.6% from the IPO issue price.

With the IPO having received a massive 71.26 times subscription, including 172.03 times subscription in the QIB category, the stock’s performance in the coming sessions will be closely watched by investors.

The stock prices mentioned above are based on the market data provided and are as of 11:30 AM on September 1, 2026. This article is for informational purposes only and should not be considered investment advice.

Disclaimer – The stock/s and indices mentioned in this article are discussed solely for informational and educational purposes. It should not be construed as investment advice or a recommendation to buy or sell any securities. Investors should conduct their own research or consult a financial advisor before making any investment decisions. Investments in securities markets are subject to market risks. Read all the related documents carefully before investing.